|
|
News Breaks | | | | November 12, 2012 | | 08:46 EDT |  | WPI | Watson Pharmaceuticals generic Revatio receives FDA approval
Watson Pharmaceuticals announced that its subsidiary Watson Laboratories has received approval from the FDA on its Abbreviated New Drug Application for Sildenafil Tablets, 20 mg, the generic equivalent to Pfizer's Revatio. Watson intends to begin shipping the product in the near future. Revatio is indicated for the treatment of pulmonary arterial hypertension in adults to improve exercise ability and delay clinical worsening. For the 12 months ending September 30, Revatio tablets had total U.S. sales of approximately $339M according to IMS Health data. | |
|
News For WPI From The Last 14 Days Check below for free stories on WPI the last two weeks. |
|
|
| There are no results for WPI |
|
|
|
|
|
|
